APA (7th ed.) Citation

Qin, Y., Jiang, Q., Lai, Y., Jiang, H., Shi, H., Zhao, X., . . . Huang, X. (2017). Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. Leukemia & Lymphoma, 58(6), 1384. https://doi.org/10.1080/10428194.2016.1239260

Chicago Style (17th ed.) Citation

Qin, Ya-Zhen, Qian Jiang, Yue-Yun Lai, Hao Jiang, Hong-Xia Shi, Xiao-Su Zhao, Yan-Rong Liu, and Xiao-Jun Huang. "Concordant Optimal Molecular and Cytogenetic Responses at Both 3 and 6 Months Predict a Higher Probability of MR4.5 Achievement in Patients with Chronic Myeloid Leukemia Treated with Imatinib." Leukemia & Lymphoma 58, no. 6 (2017): 1384. https://doi.org/10.1080/10428194.2016.1239260.

MLA (9th ed.) Citation

Qin, Ya-Zhen, et al. "Concordant Optimal Molecular and Cytogenetic Responses at Both 3 and 6 Months Predict a Higher Probability of MR4.5 Achievement in Patients with Chronic Myeloid Leukemia Treated with Imatinib." Leukemia & Lymphoma, vol. 58, no. 6, 2017, p. 1384, https://doi.org/10.1080/10428194.2016.1239260.